Identification Generic Name (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide DrugBank Accession Number DB06837 Background Not Available Type Small Molecule Groups Experimental Structure 
 
 
 3D Download  MOL SDF 3D-SDF PDB SMILES InChI 
 
 
  Similar Structures Structure for (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide (DB06837) ×  Close Weight Average: 370.3991  Monoisotopic: 370.152871824  Chemical Formula C 20 H 22 N 2 O 5 Synonyms Not Available Pharmacology Indication Not Available Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets. See how     Build, train, & validate predictive machine-learning models with structured datasets. See how Contraindications & Blackbox Warnings Avoid life-threatening adverse drug events Improve clinical decision support with information on  contraindications & blackbox warnings, population restrictions, harmful risks, & more. Learn more     Avoid life-threatening adverse drug events & improve clinical decision support. Learn more Pharmacodynamics Not Available Mechanism of action Target Actions Organism U A disintegrin and metalloproteinase with thrombospondin motifs 5 Not Available Humans Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half-life Not Available Clearance Not Available Adverse Effects Improve decision support & research outcomes With structured adverse effects data, including:  blackbox warnings, adverse reactions, warning & precautions, & incidence rates. Learn more     Improve decision support & research outcomes with our structured adverse effects data. Learn more Toxicity Not Available Pathways Not Available Pharmacogenomic Effects/ADRs  
 
 
 Not Available Interactions Drug Interactions  
 
 
 This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.  Not Available Food Interactions Not Available Categories Drug Categories Not Available Chemical Taxonomy Provided by  Classyfire Description This compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring. Kingdom Organic compounds Super Class Benzenoids Class Indanes Sub Class Not Available Direct Parent Indanes Alternative Parents 1-hydroxy-4-unsubstituted benzenoids  /  1-hydroxy-2-unsubstituted benzenoids  /  N-acyl amines  /  Benzene and substituted derivatives  /  Secondary carboxylic acid amides  /  Secondary alcohols  /  Hydroxamic acids  /  Organopnictogen compounds  /  Organonitrogen compounds  /  Organic oxides  /  Hydrocarbon derivatives  /  Carbonyl compounds 
 
 
  show 2 more Substituents 1-hydroxy-2-unsubstituted benzenoid  /  1-hydroxy-4-unsubstituted benzenoid  /  Alcohol  /  Aromatic homopolycyclic compound  /  Carbonyl group  /  Carboxamide group  /  Carboxylic acid derivative  /  Fatty acyl  /  Fatty amide  /  Hydrocarbon derivative  /  Hydroxamic acid  /  Indane  /  Monocyclic benzene moiety  /  N-acyl-amine  /  Organic nitrogen compound  /  Organic oxide  /  Organic oxygen compound  /  Organonitrogen compound  /  Organooxygen compound  /  Organopnictogen compound  /  Phenol  /  Secondary alcohol  /  Secondary carboxylic acid amide 
 
 
  show 13 more Molecular Framework Aromatic homopolycyclic compounds External Descriptors Not Available Affected organisms Not Available Chemical Identifiers UNII Not Available CAS number Not Available InChI Key VXDKQRWTOJFQKH-BJZITVGISA-N InChI InChI=1S/C20H22N2O5/c23-15-6-3-4-12(9-15)8-14(11-18(25)22-27)20(26)21-19-16-7-2-1-5-13(16)10-17(19)24/h1-7,9,14,17,19,23-24,27H,8,10-11H2,(H,21,26)(H,22,25)/t14-,17-,19+/m1/s1 IUPAC Name (2R)-N'-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2-[(3-hydroxyphenyl)methyl]butanediamide SMILES [H][C@](CC(=O)NO)(CC1=CC(O)=CC=C1)C(=O)N[C@@]1([H])C2=C(C[C@@]1([H])O)C=CC=C2 References General References Not Available External Links PubChem Compound 11143173 PubChem Substance 99443308 ChemSpider 9318285 BindingDB 50104965 ChEMBL CHEMBL8943 ZINC ZINC000013436282 PDBe Ligand 099 PDB Entries 3hyg Clinical Trials Clinical Trials  
 
 
 Phase Status Purpose Conditions Count Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage Forms Not Available Prices Not Available Patents Not Available Properties State Solid Experimental Properties Not Available Predicted Properties Property Value Source Water Solubility 0.162 mg/mL ALOGPS logP 0.7 ALOGPS logP 1.22 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 8.79 Chemaxon pKa (Strongest Basic) -1.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 118.89 Å 2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 98.65 m 3 ·mol -1 Chemaxon Polarizability 38.08 Å 3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon Predicted ADMET Features Property Value Probability Human Intestinal Absorption + 0.9536 Blood Brain Barrier + 0.715 Caco-2 permeable - 0.7405 P-glycoprotein substrate Non-substrate 0.5678 P-glycoprotein inhibitor I Non-inhibitor 0.913 P-glycoprotein inhibitor II Non-inhibitor 0.9797 Renal organic cation transporter Non-inhibitor 0.9441 CYP450 2C9 substrate Non-substrate 0.7678 CYP450 2D6 substrate Non-substrate 0.8302 CYP450 3A4 substrate Substrate 0.5502 CYP450 1A2 substrate Non-inhibitor 0.6807 CYP450 2C9 inhibitor Non-inhibitor 0.8171 CYP450 2D6 inhibitor Non-inhibitor 0.8849 CYP450 2C19 inhibitor Non-inhibitor 0.7033 CYP450 3A4 inhibitor Non-inhibitor 0.8353 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7328 Ames test AMES toxic 0.6418 Carcinogenicity Non-carcinogens 0.8439 Biodegradation Not ready biodegradable 0.9082 Rat acute toxicity 2.4098 LD50, mol/kg  Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9838 hERG inhibition (predictor II) Non-inhibitor 0.7662    ADMET data is predicted using  admetSAR , a free tool for evaluating chemical ADMET properties. ( 23092397 )  Spectra Mass Spec (NIST) Not Available Spectra Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available Targets Build, predict & validate machine-learning models Use our structured and evidence-based datasets to  unlock newinsights and accelerate drug research. Learn more     Use our structured and evidence-based datasets to unlock new insights and accelerate drug research. Learn more 
 
 
  Details 1.  A disintegrin and metalloproteinase with thrombospondin motifs 5 Kind Protein Organism Humans Pharmacological action Unknown General Function Zinc ion binding Specific Function Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. May play a role in proteolytic proc... Gene Name ADAMTS5 Uniprot ID Q9UNA0 Uniprot Name A disintegrin and metalloproteinase with thrombospondin motifs 5 Molecular Weight 101716.955 Da References Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [ Article ]  × Identify potential medication risks Easily compare up to 40 drugs with our drug interaction checker. Get severity rating, description, and management advice.  Learn more      Drug created at September 15, 2010 21:17 / Updated at June 12, 2020 16:52 